analyst
RG
NASDAQ · RGNX
REGENXBIO Inc.
Healthcare · Biotechnology
$10.66
Down-$0.25 (-2.29%)
Updated Aug 14, 2026, 2:44 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 650.96M
- P/E ratio
- -3.74
- Dividend yield
- 0.00%
- 52-week range
- $5.46 – $15.88
- Volume
- 805.58K
- Avg. volume
- 586.76K
Price performance
RGNX price history
1M range · 20 trading sessions · Daily adjusted prices
RGNX closed at $10.91 after 20 trading sessions, down 2.59% for the selected period.
- Last close
- $10.91
- Period change
- -2.59%
- Period low
- $9.60
- Period high
- $11.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $10.77 | $11.21 | $10.675 | $10.91 | 877.34K |
| Aug 11, 2026 | $10.56 | $10.79 | $10.15 | $10.65 | 881.2K |
| Aug 10, 2026 | $10.52 | $10.87 | $10.27 | $10.42 | 988.83K |
| Aug 7, 2026 | $11.05 | $11.39 | $10.31 | $10.72 | 1.39M |
| Aug 6, 2026 | $11.28 | $11.50 | $10.85 | $11.28 | 1.77M |
| Aug 5, 2026 | $10.32 | $10.79 | $10.20 | $10.50 | 1.52M |
| Aug 4, 2026 | $10.13 | $10.43 | $9.871 | $10.30 | 968.72K |
| Aug 3, 2026 | $9.75 | $10.01 | $9.31 | $9.96 | 812.9K |
| Jul 31, 2026 | $10.25 | $10.38 | $9.635 | $9.69 | 1.16M |
| Jul 30, 2026 | $9.75 | $10.14 | $9.53 | $10.12 | 1.22M |
| Jul 29, 2026 | $9.65 | $9.8999 | $9.46 | $9.62 | 1.09M |
| Jul 28, 2026 | $9.59 | $9.77 | $9.175 | $9.60 | 1.39M |
| Jul 27, 2026 | $10.05 | $10.51 | $9.655 | $9.71 | 1.25M |
| Jul 24, 2026 | $10.24 | $10.3359 | $9.57 | $9.73 | 974.33K |
| Jul 23, 2026 | $9.94 | $10.32 | $9.675 | $10.25 | 1.36M |
| Jul 22, 2026 | $10.08 | $10.50 | $10.0109 | $10.20 | 1.15M |
| Jul 21, 2026 | $10.19 | $10.49 | $9.9209 | $10.34 | 1.98M |
| Jul 20, 2026 | $10.01 | $10.78 | $10.01 | $10.32 | 2.28M |
| Jul 17, 2026 | $8.99 | $10.24 | $8.42 | $9.89 | 7.52M |
| Jul 16, 2026 | $12.15 | $12.15 | $11.015 | $11.20 | 2.01M |
Latest RGNX news
The latest Smart Investors Daily articles mentioning RGNX.
Stock researchResearch & News · Analysis
Loading stock research…

